Reneuron Share Discussion Threads

[small crow] 20/4/2021 14:56

Next leg-up soon.

[small crow] 19/4/2021 14:08

Lonely one-buy! Must be a signal....

[lauders] 16/4/2021 05:32

Don't think the latest presentation has been shared here yet:

Looking forwards to seeing more exosome deals while we wait for the hRPC data to arrive.

[dickbush] 12/4/2021 15:01

...and zho.

...and those who pushed it up on Friday, ignorant, I'm sure, that the article would appear over the weekend.

[dickbush] 12/4/2021 10:27

My thanks to Richard Griffiths and the Mail on Sunday.

[zho] 11/4/2021 08:37

Former City broker Richard Griffiths has been dubbed the ‘Welsh Wizard’ for his stock market bets, and has brought plenty of fellow investors under his spell.

So market watchers take note. It has emerged that the Jersey dweller has taken a 7 per cent stake in ReNeuron.

The small-cap is a stem cell research specialist which recently raised £15 million to expand a study of its treatment for a degenerative eye disease.

The shares have rallied over the last month, up more than 30 per cent at £1.33. Griffiths’ followers will have their eyes trained on this one

[x54v] 09/4/2021 17:56

Breakout to a new 50 day high on good volume.

Looks primed for a move up.

[bradders51] 09/4/2021 17:39

Looking good for Monday.
Another Holdings RNS maybe ??

[dickbush] 09/4/2021 14:28

There may not be much progress on the operating front but, at least, the share price is.

[small crow] 09/4/2021 13:33

Are we looking at breakout at the end of one of those flag thingies? If so, my boots will be readied for filling.

[whatno] 08/4/2021 16:00

Their schedule has slipped again. They have still only treated 3 people in the Ph2a extension. Could this go any slower!

[bradders51] 06/4/2021 12:02

ShareTalk with Olav today
hxxps://www.share-talk.com/olav-hellebo-ceo-of-reneuron-group-plc-rene-l-interview/#gs.xjequd

Shame nothing about exosome technology.

[martinfrench] 06/4/2021 11:11

agreed

its time for the rubber to hit the road

[deutsch4] 31/3/2021 09:15

We sound like a solution looking for a problem all the time? - Seems to be a continuous dialogue to keep the funds flowing? - When do we set sail?

[supernumerary] 31/3/2021 00:05

ReNeuron Group plc

07 May 2020

ReNeuron Group plc CTX cell line shows further potential

ReNeuron's CTX cell line shows further potential

Newly published positive efficacy data in an accepted model of Huntington's disease

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new positive data relating to its CTX cell therapy candidate have been published in the leading peer-reviewed scientific journal Stem Cells, in a paper entitled "Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioural and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease".

The new data show for the first time that ReNeuron's CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder.

This study was led by Professor Jihwan Song from the Department of Biomedical Science at the CHA University in South Korea and the paper is accessible at the following link:



[ ... ]

[whatno] 30/3/2021 23:45

There was some pre-clinical work done by a Professor at a university in South Korea a few years back.

[the stigologist] 30/3/2021 23:20

Do we have a HD product?

[supernumerary] 30/3/2021 20:06

While I'm on the subject :¬)

There's an open goal awaiting the right striker...



Wave culls leading Huntington's meds as shares go under after rival Roche hit by similar fate

Just over a year after Wave Life Sciences cut staffers, threw out a Duchenne muscular dystrophy med and saw its Huntington's disease drug flop in a key test, the waves come crashing down again for the biotech.

In an update posted after-hours Monday evening, Wave said data out of a midstage tests for two of its Huntington’s drugs, WVE-120102 and WVE-120101, were simply too poor to keep going, and they have been axed.

WVE-120102 works as an antisense oligonucleotide designed to stop the body from making a mutant huntingtin (mHTT) protein linked to the disease. The writing was already on the wall for the experimental drug after it failed to beat or match Roche and Ionis’ rival Huntington’s med tominersen.

WVE-120101, meanwhile, also works as an antisense oligonucleotide and interferes with the mutant mRNA copy of the huntingtin (HTT) gene. It does this by binding to the mutant mRNA, preventing the cell’s protein-making machinery from reading it. This prevents abnormal Huntingtin protein from being produced.

Across two trials, however, the drugs failed to perform. In the so-called PRECISION-HD2 core trial, results from all participants (88 in total) showed “no statistically significant change” in mHTT when pitted against a dummy treatment, either with single or multiple doses of WVE-120102.

In an open-label test, too, the data were poor and “inconsistent,” the biotech said. A similar testing theory was also behind its other asset WVE-120101, and, because of the failure seen for the former drug, the biotech is also cutting its losses here.

“Given these and results from Wave’s previous clinical trials, as well as current understanding of the limitations of the company’s first-generation candidates, Wave will also stop clinical development of WVE-120101,” the company said in a statement.

This is a notoriously tough area: Huntingdon’s disease has few success stories in R&D and is a tricky target. Just ask Roche and Ionis, which earlier this month stopped work on tominersen, also known as IONIS-HTTRx and RG6042, which is designed to reduce production of HTT.

[ ... ]

[deutsch4] 30/3/2021 09:09

Closer yes. Lets hope it's not already in his pocket?

[rayrac] 30/3/2021 07:29

Would he keep buying on poor expectations? Bet he’s closer to the action than we are.

[ayl30] 30/3/2021 07:19

Good to see Griffiths taking more shares

[deutsch4] 24/3/2021 09:15

The product we focus on here changes all the time. Hand sanitiser next? - Hop, skip, but no jump?

[supernumerary] 23/3/2021 16:36

Roche has stopped a phase 3 Huntington’s disease clinical trial after an interim review of the data. The preplanned review found no new safety signals associated with Ionis Pharmaceuticals-partnered antisense drug tominersen, suggesting lack of efficacy may have driven the decision to stop the trial.

Tominersen, also known as IONIS-HTTRx and RG6042, is designed to reduce production of HTT, the protein that in its mutated form drives the rare genetic, progressive condition Huntington’s. HTT is a validated target, but difficulties drugging the protein via traditional modalities means there remains a major unmet need in Huntington’s, leading companies including Ionis to try to come at the problem from a new angle.

Ionis’ work led to a licensing deal with Roche in 2017 and forecasts of $5 billion peak annual sales for antisense therapy tominersen. “Given the unmet medical need, with no therapies approved to slow progression of this rare disease, tominersen was widely acknowledged to be a potential high risk but blockbuster reward asset in Roche's pipeline,” analysts at Jefferies wrote in a note to investors.

[ ... ]

The failure of tominersen creates a potential opportunity for other developers of Huntington’s drugs. Wave Life Sciences and Takeda are partnered on two antisense therapies that are in phase 1/2 trials. Takeda also recently picked up a preclinical mRNA translation modulator through a deal with Anima Biotech, and Arvinas is exploring the application of its protein degradation platform to the disease.

[bradders51] 22/3/2021 12:07

I think the recent major holding RNS's tell a different story.